In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990’s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day. The mission of the 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients.

This two and a half day conference is carefully balanced to cover the wide range of topics on peritoneal metastases. It will feature keynote lectures, didactic sessions, debates, meet the professor sessions with case presentations interspersed where appropriate. Extended discussions with elite panels and extensive audience participation is encouraged at this meeting. Individual paper sessions and abstract poster presentations will also be included in the meeting. Additionally, the program will include two satellite programs on Saturday focusing on peritoneal metastases imaging and pharmacology of chemotherapy treatments.
LEARNING OBJECTIVES

• Utilize available data to determine optimal treatment options including cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (colorectal, gastric cancer, ovarian cancer, appendiceal cancer, peritoneal mesothelioma)

• Identify quantitative prognostic indicators to select patients who will most likely benefit from cytoreductive surgery with HIPEC

• Optimize patient care by discussing the use of the appropriate clinical pathways, patient protocols, and surgical procedures

• Evaluate the potential efficacy of drugs for use in intraperitoneal or intravenous administrations in the treatment of peritoneal metastases with special emphasis on chemotherapy treatments used in the operating room

• Discuss patient selection, surgical technique and management of standardized HIPEC regiments resulting in improved patient outcomes

• Distinguish patients at risk for carcinomatosis during early phases

TARGET AUDIENCE

This conference is intended for surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, gastroenterologists, gynecologists, pharmacologists, pathologists, advanced practice clinicians, and other healthcare professionals interested in peritoneal surface oncology.

CME ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedStar Georgetown University Hospital and MedStar Washington Hospital Center. MedStar Georgetown University Hospital is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

MedStar Georgetown University Hospital designates this live activity for a maximum of 26 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

For the purpose of recertification, the American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. Nurses who attend a Category 1 CME certified activity can complete the continuing education hours section of the ANCC Professional Development Record in order to document the courses attended and the hours obtained.
COURSE DIRECTORS

Paul H. Sugarbaker, MD, FACS, FRCS
MedStar Washington Hospital Center
Washington, DC, USA

SCIENTIFIC ORGANIZING COMMITTEE

David L. Bartlett, MD
University of Pittsburgh Medical Center
Pittsburgh, PA, USA

Marcello Deraco, MD
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, ITALY

Olivier Glehen, MD, PhD
Hospitalier Lyon Sud
Lyon, FRANCE

Diane Goere, MD, PhD
Institute Gustave Roussy
Paris, FRANCE

Santiago Gonzalez-Moreno, MD, PhD
MD Anderson Cancer Center Madrid
Madrid, SPAIN

Yan Li, MD, PhD
Beijing Shijitan Hospital
Beijing, CHINA

Brendan J. Moran, MCh, FRCS, FRC SI
The North Hampshire Hospitals
Basingstoke, UNITED KINGDOM

David Morris, MD
St. George Hospital
Kogarah, AUSTRALIA

Pompiliu Piso, MD, PhD
Hospital Barmherzige Brueder
Regensburg, GERMANY

Beate S. Rau, MD, PhD
Charité Campus Mitte University Hospital
Berlin, GERMANY

Vic Verwaal, MD
Aarhus University Hospital
Aarhus, DENMARK

Yutaka Yonemura, MD, PhD
Kishiwada Tokushukai Hospital
Osaka, JAPAN

Faculty

Nita Ahuja, MD
Johns Hopkins University
Baltimore, MD, USA

David S. Alberts, MD
University of Arizona Cancer Center
Tucson, AZ, USA

H. Richard Alexander Jr., MD
University of Maryland Medical Center
Baltimore, MD, USA

Suzanne Alves, CNS
Peritoneal Malignancy Institute
Basingstoke, UNITED KINGDOM

Luca Ansaloni, MD
Papa Giovanni XXIII Hospital
Bergamo, ITALY

Alvaro Arjona-Sanchez, MD, PhD
Hospital U. Reina Sofia, Cordoba
Cordoba, SPAIN

Naoual Bakrin, MD, PhD
Le Centre Hospitalier Lyon Sud
Lyon, FRANCE

Dario Baratti, MD
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, ITALY

Joel M. Baumgartner, MD, MAS, FACS
University of California, San Diego
San Diego, CA, USA

Lana Bijelic, MD
INOVA Health System
Falls Church, VA, USA

Gina Brown, MD, FRCR
Royal Marsden NHS Foundation Trust
London, UNITED KINGDOM

Peter H. Cashin, MD, PhD
Uppsala University
Uppsala, SWEDEN

Tom Cecil, BM, DM
Hampshire Hospitals
Basingstoke, UNITED KINGDOM

Wim Ceelen, MD, PhD
Ghent University
Ghent, BELGIUM

John K. Chan, MD
Palo Alto Medical Foundation
San Francisco, CA, USA

Dennis S. Chi, MD
Memorial Sloan Kettering Cancer Center
New York, NY, USA

Jean-Marc Classe, MD, PhD
Institut de Cancérologie de l’Ouest
Saint-Herblain
Nantes, FRANCE

Eelco de Bree, MD, PhD
University Hospital Heraklion
Heraklion, GREECE

Ignace H. de Hingh, MD, PhD
Catharina Cancer Institute
Eindhoven, THE NETHERLANDS

Clarisse Dromain, MD, PhD
Institute Gustave Roussy
Paris, FRANCE
Jesus Esquivel, MD  
Cancer Treatment Centers of America  
Philadelphia, PA, USA

Anna Fagotti, MD, PhD  
Agostino Gemelli University  
Rome, ITALY

Francois-Noel Gilly, MD, PhD  
Hospices Civils de Lyon  
Lyon, FRANCE

Evgenia A. Halkia, MD  
Athens General Clinic  
Athens, GREECE

Nader N. Hanna, MD  
University of Maryland School of Medicine  
Baltimore, MD, USA

Richard A. Hoefer Jr., DO  
Sentara Surgery Specialists  
Newport News, VA, USA

Charles Honore, MD, PhD  
Institute Gustave Roussy  
Paris, FRANCE

Marybeth S. Hughes, MD, FACS  
National Cancer Institute  
Bethesda, MD, USA

James S. Jelinek, MD  
MedStar Washington Hospital Center  
Washington, DC, USA

Helen M. Kennedy, RN, STN  
St. George Hospital  
Sydney, AUSTRALIA

Joji Kitayama, MD  
Jichi Medical University  
Tokyo, JAPAN

Shigeki Kusamura, MD, PhD  
Fondazione IRCCS - Istituto Nazionale dei Tumori  
Milan, ITALY

Laura A. Lambert, MD  
University of Massachusetts Medical School  
Worcester, MA, USA

Edward A. Levine, MD  
Wake Forest University  
Winston-Salem, NC, USA

Gabriel Liberale, MD  
Institut Jules Bordet  
Brussels, BELGIUM

Faheez Mohamed, MD  
Peritoneal Malignancy Institute  
Basingstoke, UNITED KINGDOM

Samantha A. Moritz, PA-C  
MedStar Washington Hospital Center  
Washington, DC, USA

Garrett M. Nash, MD, MPH  
Memorial Sloan Kettering Cancer Center  
New York, NY, USA

Sang-Yoon Park, MD, PhD  
National Cancer Center  
Goyang, REPUBLIC OF KOREA

Marc Pocard, MD, PhD  
Lariboisière Hospital  
St. Louis Hospital  
Paris, FRANCE

Francois Quenet, MD  
Institut Du Cancer De Montpellier  
Montpellier, FRANCE

Steven A. Rosenberg, MD, PhD  
National Cancer Institute  
Bethesda, MD, USA

Pascal Rousset, MD, PhD  
Centre Hospitalier Lyon Sud  
Lyon, FRANCE

David P. Ryan, MD  
Massachusetts General Hospital  
Boston, MA, USA

Paolo Sammartino, MD, PhD  
Sapienza University of Rome  
Rome, ITALY

Armando Sardi, MD, FACS  
Mercy Medical Center  
Baltimore, MD, USA

John D. Spiliotis, MD, PhD  
Metaxa Cancer Hospital  
Pireus, GREECE

Pieter J. Tanis, MD, PhD  
Academic Medical Centre  
Amsterdam, THE NETHERLANDS

Antonios-Apostolos K. Tentes, MD, PhD  
Metropolitan Hospital  
Athens, GREECE

Kiran K. Turaga, MD, MPH  
University of Chicago  
Chicago, IL, USA

Kurt Van der Speeten, MD, PhD  
Ziekenhuis Oost-Limburg  
Hasselt, BELGIUM

Willemien van Driel, MD, PhD  
Netherlands Cancer Institute- Antoni Van Leeuwenhoek  
Amsterdam, THE NETHERLANDS

Stephanie L. Wethington, MD  
MedStar Washington Hospital Center  
Washington, DC, USA

Frans A.N. Zoetmulder, MD, PhD  
Zomba Central Hospital  
Zomba, MALAWI
Wednesday, November 16

6:00 PM Registration & Welcome Reception

Thursday, November 17

7:00 AM Registration & Breakfast

8:00 AM Welcome Remarks
Paul H. Sugarbaker, MD, FACS, FRCS

8:15 AM Welcome Comments from Local Dignitary
Steven A. Rosenberg, MD, PhD

SESSION I: UPDATE ON CLINICAL TRIALS IN COLORECTAL CANCER
Moderators: Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS

PROACTIVE PROTOCOLS:
8:30 AM ProphyloCHIP: CRS and HIPEC with Second-Look Surgery
Diane Goere, MD, PhD

8:40 AM PRODIGE 7: Adjuvant ± HIPEC for Peritoneal Metastases from Colon Cancer
Francois Quenet, MD

8:50 AM COLOPEC: Adjuvant HIPEC for Primary Colon Cancer
Pieter J. Tanis, MD, PhD

9:00 AM PROMENADE: Prophylactic HIPEC for Primary Colon Cancer
Paolo Sammartino, MD, PhD

TREATMENT PROTOCOLS:
9:10 AM ICARuS EPIC FUDR versus HIPEC after Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum with Isolated Peritoneal Metastasis
Garrett M. Nash, MD, MPH

9:20 AM Surgery and Oxaliplatin or Mitomycin C in Treating Patients with Tumors of the Appendix
Edward A. Levine, MD

9:30 AM Cytoreduction and Intraperitoneal Chemotherapy versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
Peter H. Cashin, MD, PhD

9:40 AM COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer
Pompiliu Piso, MD, PhD

9:50 AM Current Status and Future Prospects for Clinical Trials in Peritoneal Metastases from Colorectal Cancer
Moderators: Marc Pocard, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS

10:30 AM Break
SESSION II: UPDATE ON CLINICAL TRIALS IN OVARIAN CANCER
Moderators: Luca Ansaloni, MD; Dennis S. Chi, MD

11:00 AM CRS and HIPEC in Recurrent Ovarian Cancer
John D. Spiliotis, MD, PhD

11:10 AM HIPEC with Carboplatin for Recurrent Ovarian Cancer, Phase II
Dennis S. Chi, MD

11:20 AM CHIPOR CRS with or without HIPEC for Relapsed Ovarian Cancer
Jean-Marc Classe, MD, PhD

11:30 AM CHORINE CRS with or without HIPEC Upfront for Primary Ovarian Cancer
Luca Ansaloni, MD

11:40 AM HORSE CRS with or without HIPEC in Ovarian Cancer Recurrence
Anna Fagotti, MD, PhD

11:50 AM Secondary Debunking Surgery ± Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer
Willemien van Driel, MD, PhD

12:00 PM Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Armando Sardi, MD, FACS

12:10 PM HIPEC in Primary Ovarian Cancer, NCC Korea
Sang-Yoon Park, MD, PhD

12:20 PM Gynecologic Oncology Group 252, IP Carboplatin versus IP Cisplatin
John K. Chan, MD

12:30 PM Current Status and Future Prospects for Clinical Trials in Ovarian Cancer
Moderators: Luca Ansaloni, MD and Dennis S. Chi, MD
Panelists: J. Chan, D. Chi, J. Classe; A. Fagotti, S. Park, A. Sardi, J. Spiliotis, W. van Driel

1:00 PM Lunch & Visit the Posters and Exhibits

SESSION III
Moderator: David Morris, MD

2:00 PM Keynote Lecture (1): Animal Models: What Can They Tell Us about the Management of Peritoneal Metastases
Ignace H. de Hingh, MD, PhD

2:30 PM Debate (1): Adjuvant HIPEC is Superior to Second-look Surgery with HIPEC in High Risk Primary Colorectal Cancer for Peritoneal Metastases
Paolo Sammartino, MD, PhD (Pro) vs. Diane Goere, MD, PhD (Con)

3:00 PM Presentation of Best Abstracts (1-4)

4:00 PM Break

SESSION IV
Moderator: Diane Goere, MD, PhD

4:30 PM Debate (2): CRS and HIPEC is the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases
Wim Ceelen, MD, PhD (Pro) vs. David P. Ryan, MD (Con)

5:00 PM Case Presentations (1): Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer
Moderators: Dario Baratti, MD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: D. Bartlett, S. Gonzalez-Moreno, M. Pocard, D. Ryan, V. Verwaal

NETWORKING WELCOME RECEPTION
6:00 PM
Meet the Professor Breakfast Sessions

On Friday November 18th and Saturday November 19th, 2016, the 10th International Congress on Peritoneal Surface Malignancies will host (10) morning sessions that will also include a continental breakfast. Each session will highlight a specific topic in a small group setting with internationally renowned leaders in the field. The breakout sessions are listed below. Space is limited; please make sure to select one breakout session per day in your registration to confirm participation.

FRIDAY, NOVEMBER 18, 2016 | 6:30 AM – 8:00 AM

1. Drugs, Doses, and Duration of Treatments to Standardize HIPEC and EPIC for Colorectal, Appendiceal, Gastric, Ovarian, and Peritoneal Mesothelioma
   Wim Ceelen, MD, PhD; Eelco de Bree, MD, PhD; Kurt Van der Speeten, MD, PhD

2. Molecular Assessment in the Management of Peritoneal Metastases
   Nita Ahuja, MD; H. Richard Alexander Jr., MD; Edward A. Levine, MD

3. Proactive Management of Colorectal and other Cancers using Adjuvant HIPEC or Second-Look Surgery
   Tom Cecil, BM, DM; Diane Goere, MD, PhD; Charles Honore, MD, PhD; Gabriel Liberale, MD; David Morris, MD; Pieter J. Tanis, MD, PhD

4. Starting a New Peritoneal Surface Oncology Program
   Dario Baratti, MD; Dennis S. Chi, MD; Beate S. Rau, MD, PhD; Vic Verwaal, MD

5. NIPS and Surgery for Gastric Cancer
   Joji Kitayama, MD; Francois Quenet, MD; Yutaka Yonemura, MD, PhD

6. ESSO/PSOGI Certificate in Peritoneal Surface Oncology
   Marcello Deraco, MD; Santiago Gonzalez-Moreno, MD, PhD

7. Unusual Diseases are Treated by CRS and HIPEC: How to Select Patients who will Benefit
   Luca Ansaloni, MD; Lana Bijelic, MD; Marybeth S. Hughes, MD, FACS; Paul H. Sugarbaker, MD, FACS, FRCS

8. Neoadjuvant, Adjuvant and Long-term IP/IV Chemotherapy, HIPEC, EPIC for Ovarian Cancer
   Naoual Bakrin, MD, PhD; Jean-Marc Classe, MD, PhD; Anna Fagotti, MD, PhD; Evgenia A. Halkia, MD; Sang-Yoon Park, MD, PhD; Willemien van Driel, MD, PhD; Stephanie L. Wethington, MD

9. Pseudomyxoma Peritonei: Natural History and Treatment
   Yan Li, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI

10. Nurses, APCs and Allied Healthcare Professionals: Patient’s Journey with Peritoneal Malignancy - Part 1
    Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Laura A. Lambert, MD; Samantha A. Moritz, PA

Underline = Session Chairperson
Call for Abstracts

The 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) aims at improving the knowledge, treatment and outcome regarding peritoneal surface malignancies. The Scientific Organizing Committee requests participants to submit an abstract to present at the PSOGI 2016 conference. In order to promote multidisciplinary discussions during the conference, all involved disciplines such as surgery, radiology, medical oncology, pathology, and pharmacology are encouraged to submit abstracts to the program. PSOGI 2016 intends to create sufficient room for papers and posters to be presented. Selected abstracts will be incorporated into the plenary sessions for oral presentation.

RECOGNITION

Selected authors will be asked to provide an abstract poster at the meeting, November 17-19, 2016. All abstracts will be published in the official PSOGI 2016 program book.

SUBMISSION DETAILS

- All abstract submitters will be notified of acceptance status no later than September 2, 2016.
- If you have any questions, please call 202-780-1655 or send an email to psogi2016@gmail.com.

For categories and information regarding rules and regulations, please visit www.psogi2016.com.

SATURDAY, NOVEMBER 19, 2016 | 6:30 AM – 8:00 AM

   H. Richard Alexander Jr., MD; Marcello Deraco, MD; Kiran K. Turaga, MD, MPH

12. Pseudomyxoma Peritonei: Follow-up and Management of Recurrent Disease
   Tom Cecil, BM, DM; Nader N. Hanna, MD; John D. Spiliotis, MD, PhD

13. Intrapertitoneal Ports: When, Where, Why, How, Always or Never?
   Lana Bijelic, MD; John K. Chan, MD; Sang-Yoon Park, MD, PhD

14. Peritoneal Metastases from Small Bowel Adenocarcinoma: Results of Treatment
   Eelco de Bree, MD, PhD; Ignace H. de Hingh, MD, PhD; Yutaka Yonemura, MD, PhD

15. Surgical Complications and Return to the OR
   Richard A. Hoefer Jr., DO; Pompiliu Piso, MD, PhD; Vic Verwaal, MD

16. Laparoscopy and Peritoneal Surface Malignancy
   Jesus Esquivel, MD; Olivier Glehen, MD, PhD; Gabriel Liberale, MD; Marc Pocard, MD, PhD; Kurt Van der Speeten, MD, PhD

17. Peritoneal Metastases and Liver Metastases
   David L. Bartlett, MD; Joel M. Baumgartner, MD, MAS, FACS; Diane Goere, MD, PhD

18. Balancing the Books for CRS and HIPEC in a Diminishing Economy, a Global Exploration
   Wim Ceelen, MD, PhD; Brendan J. Moran, MCh, FRCS, FRCSI; Garrett M. Nash, MD, MPH

19. Consensus Regarding Concerning Radiologic Features Used to Select Patients for CRS and HIPEC
   Gina Brown, MD, FRCP; Clarisse Dromain, MD, PhD; James S. Jelinek, MD; Armando Sardi, MD, FACS; Paul H. Sugarbaker, MD, FACS, FRCS

   Suzanne Alves, CNS; Helen M. Kennedy, RN, STN; Faheez Mohamed, MD; Samantha A. Moritz, PA

Underline = Session Chairperson
SESSION V: MEET THE PROFESSOR BREAKFAST SESSIONS
6:30 AM  Registration and Meet the Professor Breakfast Sessions
          (See page 8 for more Information)

SESSION VI: UPDATE ON CLINICAL TRIALS IN GASTRIC CANCER
Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD
8:15 AM  Opening Comments and Presentation of the Events of the Day
          Paul H. Sugarbaker, MD, FACS, FRCS
8:30 AM  GastriCHIP Gastrectomy ± HIPEC as Adjuvant for Primary
          Gastric Cancer
          Olivier Glehen, MD, PhD
8:40 AM  NIPOX Adjuvant Intraoperative Oxaliplatin for Gastric Cancer
          with Peritoneal Metastases
          Francois Quenet, MD
8:50 AM  GASTRIPEC Cytoreductive Surgery (CRS) with/without HIPEC in
          Gastric Cancer with Peritoneal Carcinomatosis
          Beate S. Rau, MD, PhD
9:00 AM  Phoenix GC Neoadjuvant Intraperitoneal and Systemic
          Chemotherapy (NIPS) for Gastric Cancer with Peritoneal
          Metastases
          Joji Kitayama, MD
9:10 AM  Current Status and Future Prospects for Clinical Trials in
          Gastric Cancer
          Moderators: Yan Li, MD, PhD; Beate S. Rau, MD, PhD
          Panelists: O. Glehen, J. Kitayama, F. Quenet, P. Sugarbaker

SESSION VII: UPDATE ON INTERNATIONAL PERITONEAL METASTASES REGISTRIES
Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH
9:30 AM  International Registry on Peritoneal Mesothelioma
          Shigeki Kusamura, MD, PhD
9:40 AM  Big RENAPE including Rare Diseases Treated with CRS and HIPEC
          Diane Goere, MD, PhD
9:50 AM  German Registry
          Pompiliu Piso, MD, PhD
10:00 AM Current Status and Future Prospects for Peritoneal Metastases
10:10 AM  Registries
          Moderators: Pompiliu Piso, MD, PhD; Kiran K. Turaga, MD, MPH
          Panelists: J. Esquivel, D. Goere, S. Kusamura, M. Pocard, V. Verwaal
          Break
SESSION VIII
Moderator: Beate S. Rau, MD, PhD

11:00 AM  Presentation of Best Abstracts (5-8)  
Yutaka Yonemura, MD, PhD

12:00 PM  Case Presentations (2): Peritoneal Metastases from Gastric Cancer  
Moderators: Beate S. Rau, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS  
Panelists: O. Glehen, N. Hanna, J. Kitayama, Y. Yonemura

1:00 PM  Lunch & Visit the Posters and Exhibits

SESSION IX
Moderator: Yutaka Yonemura, MD, PhD

2:00 PM  Keynote Lecture (2): Current Treatment Options for Management of Gastric Cancer with Peritoneal Metastases  
Joji Kitayama, MD

2:30 PM  Debate (3): Recurrent Ovarian Cancer: CRS and HIPEC is a Reasonable Treatment Option Now in Selected Patients  
Naoual Bakrin, MD, PhD (Pro) vs. Stephanie L. Wethington, MD (Con)

3:00 PM  Case Presentations (3): CRS and HIPEC for Unusual Diseases  
Moderators: Paul H. Sugarbaker, MD, FACS, FRCS; Vic Verwaal, MD  
Panelists: D. Bartlett, L. de Bree, M. Deraco, D. Goere, A. Tentes

4:00 PM  Break

SESSION X
Moderator: Yan Li, MD, PhD

4:30 PM  Keynote Lecture (3): Progress in the Management of Primary and Recurrent Ovarian Cancer in Cordoba, Spain  
Alvaro Arjona-Sanchez, MD, PhD

5:00 PM  Debate (4): Pharmacology and Clinical Data Show that Mitomycin C not 5-FU and High Dose Oxaliplatin is the Current Standard of Care for Peritoneal Metastases from Colon Cancer  
Joel M. Baumgartner, MD, MAS, FACS (Pro) vs. Olivier Glehen, MD, PhD (Con)

5:30 PM  Case Presentations (4): The Prevention and Treatment of Peritoneal Metastases from Ovarian Cancer  
Moderators: Anna Fagotti, MD, PhD; Paul H. Sugarbaker, MD, FACS, FRCS  
Panelists: L. Ansaloni, D. Chi, J. Spiliotis, W. van Driel, S. Wethington

6:30 PM  Closing Remarks  
Paul H. Sugarbaker, MD, FACS, FRCS

CONGRESS BANQUET WITH HISTORICAL VIDEO | 7:30 PM
Comments by Francois-Noel Gilly, MD, PhD and Frans A.N. Zoetmulder, MD, PhD

Presentation of Certificates for European School of Peritoneal Surface Oncology
SESSION XI: MEET THE PROFESSOR BREAKFAST SESSIONS
6:30 AM Registration and Meet the Professor Breakfast Sessions
(See page 9 for more Information)

SESSION XII: NEW TECHNOLOGIES TO OPTIMIZE MANAGEMENT OF
PERITONEAL SURFACE MALIGNANCY*
Moderator: David L. Bartlett, MD
8:15 AM Opening Comments and Presentation of the Events of the Day
Paul H. Sugarbaker, MD, FACS, FRCS
8:30 AM Keynote Lecture (4): Genomic Medicine as it Involves
Peritoneal Metastases
Nita Ahuja, MD
9:00 AM Preoperative Assessments
Jesus Esquivel, MD
9:20 AM Pressurized Intraperitoneal Chemotherapy (PIPAC)
Marc Pocard, MD, PhD
9:30 AM Multi-Detector CT to Identify Poor Prognostic Factors in Primary
Colorectal Cancer
Gina Brown, MD, FRCR
10:00 AM Keynote Lecture (5): Bidirectional Adjuvant Normothermic
Chemotherapy (BANC) Long-Term for Management of Ovarian
Cancer
John K. Chan, MD
10:30 AM Break

SESSION XIII: THE FUTURE IS NOW*
Moderator: H. Richard Alexander Jr., MD
11:00 AM Keynote Lecture (6): 90% of the Adverse Outcomes Occur in
10% of Patients. Can We Identify the High Risk Groups?
Charles Honore, MD, PhD
11:30 AM Case Presentations (5): Prevention and Treatment of Peritoneal
Metastases from Appendiceal Cancer
Moderators: H. Richard Alexander Jr., MD; Paul H. Sugarbaker, MD, FACS, FRCS
Panelists: D. Bartlett, S. Gonzalez-Moreno, B. Moran, D. Morris, P. Tanis
12:30 PM 10 Take Home Messages
Santiago Gonzalez-Moreno, MD, PhD
12:45 PM Closing Remarks and Looking Ahead to PSOGI Congress 2018
in Paris
Olivier Glehen; MD, PhD, Diane Goere, MD, PhD; Marc Pocard, MD, PhD;
Paul H. Sugarbaker, MD, FACS, FRCS
1:00 PM Adjourn

* In collaboration with the Society of Surgical Oncology
SESSION I
Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD

1:30 PM Pharmacodynamics of Intraperitoneal Chemotherapy
Wim Ceelen, MD, PhD

2:00 PM Pharmacokinetics of Chemotherapy Delivery by PIPAC
Marc Pocard, MD, PhD

2:30 PM Novel Approaches to Intraperitoneal Drug Delivery
David Morris, MD

3:00 PM Long-Term IP/IV Chemotherapy for Ovarian Cancer: Rationale and Pharmacology
John K. Chan, MD

3:30 PM Questions & Discussion
Moderators: Joji Kitayama, MD; Kurt Van der Speeten, MD, PhD
Panelists: W. Ceelen, J. Chan, D. Morris, M. Pocard

4:00 PM Break

SESSION II
Moderator: David Morris, MD; Marc Pocard, MD, PhD

4:30 PM Pharmacology of Intraperitoneal Chemotherapy for Ovarian Cancer
David S. Alberts, MD

5:00 PM Molecular Agents for Intraperitoneal Administration
Olivier Glehen, MD, PhD

5:30 PM Nanomicellar Drugs for Intraperitoneal Administration
Joji Kitayama, MD

6:00 PM Knowing What We Know Now, the Optimal Perioperative Chemotherapy Regimens are…
Kurt Van der Speeten, MD, PhD

6:30 PM Questions & Discussion
Moderator: David Morris, MD; Marc Pocard, MD, PhD
Panelists: D. Alberts, O. Glehen, J. Kitayama, K. Van der Speeten

7:00 PM Adjourn

SATELLITE SYMPOSIUM (OPTION 1)
Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC
This satellite symposium will describe the pharmacodynamics and pharmacokinetics of chemotherapy administered with heat in the operating room. Additionally, novel approaches to intraoperative and long-term combined intraperitoneal and systemic chemotherapy will be investigated. Exploration of ovarian cancer molecular agents for intraperitoneal administration will also take place. The program will include ample time for questions and faculty will provide key recommendations for a standardized chemotherapy regimen for peritoneal metastases.
SATELLITE SYMPOSIUM (OPTION 2)
Peritoneal Metastases Imaging
Through a collaboration of an international planning team to standardize the technology and terminology for imaging peritoneal metastases, this symposium will explore the clinical utility of radiologic studies to select patients who will benefit from the surgical treatment of peritoneal metastases.

SESSION I
Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD

1:30 PM An Initial Attempt to Standardize a Best Technology of CT, MRI, PET for Peritoneal Metastases
Clarisse Dromain, MD, PhD

2:00 PM Formulating a Lexicon of Concerning Radiologic Features
James S. Jelinek, MD

2:30 PM Description of Peritoneal Metastases by CT
Gina Brown, MD, FRCR

3:00 PM Description of Peritoneal Metastases by MRI
Pascal Rousset, MD, PhD

3:30 PM Questions & Discussion
Moderators: Clarisse Dromain, MD, PhD; James S. Jelinek, MD
Panelists: G. Brown, P. Rousset

4:00 PM Break

SESSION II
Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD

4:30 PM Optical Imaging for Detection of Peritoneal Metastases
Gabriel Liberale, MD

5:00 PM Using Radiology to Define High Risk for Peritoneal Metastases in Primary Gastrointestinal Cancer, Colon, Gastric, and Pancreas
Gina Brown, MD, FRCR

5:35 PM Peritoneal Metastases: Their Associated Clinical Features—Can PET be of Help?
Clarisse Dromain, MD, PhD

6:00 PM Is There a Minimal Required Report for Peritoneal Metastases?
Pascal Rousset, MD, PhD

6:30 PM Questions & Discussion
Moderator: Clarisse Dromain, MD, PhD; James S. Jelinek, MD
Panelists: G. Brown, G. Liberale, P. Rousset

7:00 PM Adjourn
Registration Information

REGISTRATION FEES

NOW through September 1, 2016
$500  Physician
$350  Residents/Fellow
$350  Advanced Practice Clinician
$350  Nurse
$350  Allied Health Professional

September 2 through November 15, 2016*
$700  Physician
$550  Residents/Fellow
$550  Advanced Practice Clinician
$550  Nurse
$550  Allied Health Professional

*An additional $100 will be added to onsite registrations November 16-19

Post-Conference Satellite Symposia (Additional Fee)

$150  Physician
$100  Residents/Fellow
$100  Advanced Practice Clinician
$100  Allied Health Professional

Please visit our secure website at www.psogi2016.com to register to attend. We are unable to accept registrations or cancellations by telephone.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at psogi2016@gmail.com or 202-780-1655.

CANCELLATION POLICY

Cancellations made in writing by Friday, September 30, 2016 will be subject to a 50% penalty. No refunds will be given after September 30, 2016. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call 202-780-1655 or email psogi2016@gmail.com if you any questions or need any additional information.

VENUE INFORMATION

Omni Shoreham Hotel
2500 Calvert Street, NW, Washington, DC 20008
202-234-0700

ROOM BLOCK

Room Block Rate: $239 night plus applicable tax, single or double occupancy

Please call Omni Reservations at 1-800-THE-OMNI (1-800-843-6664) to book your room today! Reservations can also be made online by visiting psogi2016. When making reservations by phone, please indicate that you are a part of the “10th International Congress on Peritoneal Surface Malignancies Group.”

Our preferred discount room block is available Monday, November 14th, 2016 through Tuesday, November 22nd, 2016. Reservation requests received after that date will be based on availability at the hotel’s prevailing rates.

The cut-off date for making reservations is Friday, October 21, 2016.
10th International Congress on Peritoneal Surface Malignancies

November 17 – 19, 2016 • Omni Shoreham Hotel • Washington, DC

Course Director:
Paul H. Sugarbaker, MD, FACS, FRCS
MedStar Washington Hospital Center
Washington, DC

www.psogi2016.com